EVENT DETAILS
Wednesday, December 5, 2018
Lombardo's
6 Billings Street,
Randolph, MA 02368
Time
8:00 AM - 5:00 PM
Total Credits
7 Contact Hour(s)
Target Audience
Nurse , Pharmacist , Pharmacy Technician
Cost
$129.00
Registration closes on 12/4/2018 at 11:00 PM
 

Registration will be held from 8:00 am - 8:30 am. Continental breakfast will be served during this time.

A plated lunch will be served from 12:00 pm - 1:00 pm.

Refreshments will be served during the afternoon programs.

 

AGENDA

Scheduled CE Activities Wednesday, December 5, 2018
  
Cases of syphilis and gonorrhea reported in Massachusetts have increased and now approach levels not seen since the early 1990s. We will examine sexually transmitted infection (STI) epidemiologic trends in greater detail, then highlight at least three STI treatment strategies relevant to pharmacists: (1) expedited partner therapy for chlamydia (treating partners of chlamydia-infected patients without examination), (2) dual drug therapy and other strategies to delay the development of multi-drug resistant gonorrhea, and (3) counseling to avoid adverse events from specific STI drug treatment regimens.
 
 
Pharmacist Learning Objectives
  • Explain current STI epidemiology in Massachusetts, including repeat infections
  • Review Massachusetts regulations pertaining to Expedited Partner Therapy for prevention of chlamydia reinfection
  • Recognize concerns related to the development of multi-drug resistant gonorrhea
  • Identify counseling messages for patients to help avoid adverse events from specific STI drug treatment regimens
Pharmacy Technician Learning Objectives
  • Explain current STI epidemiology in Massachusetts, including repeat infections
  • Review Massachusetts regulations pertaining to Expedited Partner Therapy for prevention of chlamydia reinfection
  • Recognize concerns related to the development of multi-drug resistant gonorrhea
Nurse Learning Objectives
  • Explain current STI epidemiology in Massachusetts, including repeat infections
  • Review Massachusetts regulations pertaining to Expedited Partner Therapy for prevention of chlamydia reinfection
  • Recognize concerns related to the development of multi-drug resistant gonorrhea
  • Identify counseling messages for patients to help avoid adverse events from specific STI drug treatment regimens
 
Faculty
Katherine HsuMD, MPH, FAAP
Division of STD Prevention & HIV/AIDS Surveillance Massachusetts Department of Public Health; Section of Pediatric Infectious Diseases Boston University Medical Center
 
ACPE UAN
0280-0000-18-098-L04-P (Knowledge-Based)
0280-0000-18-098-L04-T (Knowledge-Based)
0280-0000-18-098-L04-N (Knowledge-Based)
 
Credits
1.5
 
Handouts
 
Supported By
New England AIDS Education and Training Center
 

Depression impacts an estimated 6.7% of the U.S. population, making it the most common mental disorder in the United States, with many cases being undiagnosed and/or untreated.  Tragically, a diagnosis of depression increases an individual’s risk for suicide by almost twenty-fold.  Suicide, however, is a completely preventable phenomenon.  Statistically, pharmacists and pharmacy technicians find themselves staring at the perilous front line of this battle on a continuous basis.  The very front line of the battle, however, often goes unrecognized and unaddressed.  


This session seeks to review the functionality of major classes of antidepressant medications, highlighting the most common prescribing concerns among the various classes.  Additionally, the session seeks to evaluate the pharmacist and pharmacy technician’s role in recognizing suicidal behaviors and appropriate follow up actions.  

 
 
Pharmacist Learning Objectives
  • Identify the symptoms and characteristics of depression
  • Critically evaluate the relationship between depression, antidepressant medications, and suicide risk
  • Identify appropriate professional discussions and interventions in communicating with patients at an increased risk for suicide.
Pharmacy Technician Learning Objectives
  • Identify the symptoms and characteristics of depression
  • Recognize the relationship between depression, antidepressant medications, and suicide risk
  • Identify patient behaviors that may indicate an increased risk for suicide.
Nurse Learning Objectives
  • Identify the symptoms and characteristics of depression
  • Critically evaluate the relationship between depression, antidepressant medications, and suicide risk
  • Identify appropriate professional discussions and interventions in communicating with patients at an increased risk for suicide.
 
Faculty
Kevin HopeRPh
Clinical Education Specialist and Continuing Education Administrator, PharmCon, Inc.; Advisory Board Member, Paradigm Education Solutions; Nuclear Pharmacist, Triad Isotopes
 
ACPE UAN
0280-0000-18-080-L04-P (Knowledge-Based)
0280-0000-18-080-L04-T (Knowledge-Based)
0280-0000-18-080-L04-N (Knowledge-Based)
 
Credits
1.5
 
Handouts
 
Supported By
American Health Resources
 
The ADA-EASD Consensus Report, published in 2018, includes specific pharmacologic recommendations based on a patient’s profile and health history and provides instructions in the context of ASCVD, heart failure, kidney disease, weight, risk for hypoglycemia, or a need for low-cost options.   Metformin remains the preferred first-line agent. Pharmacists need to be aware of the current treatment algorithm recommendations and data supporting glucagon-like peptide 1 (GLP-1) receptor agonists and a sodium-glucose cotransporter 2 (SGLT2) inhibitors as well as the place of therapy of other available agents.
 
 
Pharmacist Learning Objectives
  • Identify appropriate strategies to incorporate the ADA/EASD 2018 consensus report for the management of hyperglycemia in patients with type 2 diabetes
  • Recognize evidence-based treatment options that optimize outcomes in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), heart failure, and chronic kidney disease
  • List drug therapy options for patients with type 2 diabetes with consideration to avoiding hypoglycemia and weight gain and minimizing cost
  • List the potential cardiovascular and renal benefits and risk of various treatment approaches for diabetes to patients and members of the healthcare team
Pharmacy Technician Learning Objectives
  • Identify the diabetes medications that are recommended by the ADA/EASD 2018 consensus report in patients with type 2 diabetes and cardiovascular and renal risks
  • Recognize the drug therapies that show evidence of benefit in improving blood sugars and decreasing risk of cardiovascular and renal events
  • Recognize drug therapies that minimize hypoglycemia and weight gain and cost considerations
Nurse Learning Objectives
  • Identify appropriate strategies to incorporate the ADA/EASD 2018 consensus report for the management of hyperglycemia in patients with type 2 diabetes
  • Recognize evidence-based treatment options that optimize outcomes in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), heart failure, and chronic kidney disease
  • List drug therapy options for patients with type 2 diabetes with consideration to avoiding hypoglycemia and weight gain and minimizing cost
  • List the potential cardiovascular and renal benefits and risk of various treatment approaches for diabetes to patients and members of the healthcare team
 
Faculty
Jennifer GoldmanPharmD, CDE, BC-ADM, FCCP
Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences
 
ACPE UAN
0280-0000-18-099-L01-P (Knowledge-Based)
0280-0000-18-099-L01-T (Knowledge-Based)
0280-0000-18-099-L01-N (Knowledge-Based)
 
Credits
2
 
Handouts
 
Supported By
American Health Resources
 
As the nation’s opiate crisis continues, pharmacy personnel often find themselves thrust into a rapidly evolving regulatory theater as various agencies seek to reduce the impact of the current crisis in the United States.  This session seeks to identify the most common methods of diversion and to examine the “red flags” that pharmacy personnel should recognize as being potentially indicative of inappropriate access.  The concept of a pharmacist’s ‘corresponding responsibility’ will be carefully examined, including DEA expectations for recordkeeping upon facility audit.  The importance of proper drug disposal will be addressed within the context of preventing unintended diversion.
 
 
Pharmacist Learning Objectives
  • Recognize required recordkeeping regulations and expectations for a DEA pharmacy audit.
  • Recognize potential “red flags” as they relate to prescriptions and/or customers
  • List common drugs of abuse and methods of diversion.
  • Identify appropriate disposal options for controlled substances.
Pharmacy Technician Learning Objectives
  • Recognize required recordkeeping regulations and expectations for a DEA pharmacy audit.
  • Recognize potential “red flags” as they relate to prescriptions and/or customers
  • List common drugs of abuse and methods of diversion.
  • Identify appropriate disposal options for controlled substances.
Nurse Learning Objectives
  • Recognize required recordkeeping regulations and expectations for a DEA pharmacy audit.
  • Recognize potential “red flags” as they relate to prescriptions and/or customers
  • List common drugs of abuse and methods of diversion.
  • Identify appropriate disposal options for controlled substances.
 
Faculty
Claire BrennanDiversion Program Manager
Drug Enforcement Administration
 
ACPE UAN
0280-0000-18-097-L03-P (Knowledge-Based)
0280-0000-18-097-L03-T (Knowledge-Based)
0280-0000-18-097-L03-N (Knowledge-Based)
 
Credits
2
 
Handouts
 
Supported By
Drug Enforcement Administration
 
 
 
 
Requirements for CE Credit
  • Participant Requirement and Statement of Credit: To receive credit, participants must fully attend each session (no partial credit will be awarded), pass in a completed attendance verification form, and using the access code provided, complete the online evaluation for each session attended. Attendance will be verified. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their
  • Pharmacists and Pharmacy Technicians: CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours where an official certificate of credit can be printed. Evaluations must be completed within 60 days of program date to receive credit.
  • Statement of Disclosure: Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.
  • Refund Policy: A full refund will be provided only if a written request is received by American Health Resources, LLC at least 48 hours prior to the program or if the program is cancelled. American Health Resources, LLC reserves the right to change the presenters, topics or seminar schedules.
 
Only Certificates of Credit issued from CPE Monitor are valid in the US.
CPE Monitor will not accept credits after 60 days from the session date.
 
Supported By:
American Health Resources, LLC.
 
Registration closes on 12/4/2018 at 11:00 PM
 

CONTINUING EDUCATION

843 488 5550 Office

843 488 5554 Fax

info@ahrevents.com Email

www.ahrevents.com Web

341 Wellness Drive, Myrtle Beach, SC 29579 Address

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyAmerican Health Resources, LLC a subsidiary of PharmCon, Inc.
Developed By: ITB, Inc.